NO984163L - Forbedret syn ved fotodynamisk terapi av °yet - Google Patents

Forbedret syn ved fotodynamisk terapi av °yet

Info

Publication number
NO984163L
NO984163L NO984163A NO984163A NO984163L NO 984163 L NO984163 L NO 984163L NO 984163 A NO984163 A NO 984163A NO 984163 A NO984163 A NO 984163A NO 984163 L NO984163 L NO 984163L
Authority
NO
Norway
Prior art keywords
photodynamic therapy
improved vision
vision
improved
photodynamic
Prior art date
Application number
NO984163A
Other languages
English (en)
Norwegian (no)
Other versions
NO984163D0 (no
Inventor
H Andrew Strong
Julia Levy
Gustav Huber
Mario Fsadni
Original Assignee
Qlt Phototherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Phototherapeutics Inc filed Critical Qlt Phototherapeutics Inc
Publication of NO984163D0 publication Critical patent/NO984163D0/no
Publication of NO984163L publication Critical patent/NO984163L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
NO984163A 1996-03-11 1998-09-10 Forbedret syn ved fotodynamisk terapi av °yet NO984163L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/613,420 US5756541A (en) 1996-03-11 1996-03-11 Vision through photodynamic therapy of the eye
PCT/CA1997/000134 WO1997033619A1 (en) 1996-03-11 1997-02-25 Improved vision through photodynamic therapy of the eye

Publications (2)

Publication Number Publication Date
NO984163D0 NO984163D0 (no) 1998-09-10
NO984163L true NO984163L (no) 1998-11-11

Family

ID=24457246

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984163A NO984163L (no) 1996-03-11 1998-09-10 Forbedret syn ved fotodynamisk terapi av °yet

Country Status (22)

Country Link
US (6) US5756541A (zh)
EP (1) EP0894009B1 (zh)
JP (2) JP2000506173A (zh)
KR (1) KR100433507B1 (zh)
CN (1) CN1104908C (zh)
AR (2) AR004422A1 (zh)
AT (1) ATE301473T1 (zh)
CA (1) CA2248087C (zh)
CZ (1) CZ299301B6 (zh)
DE (1) DE69733943T2 (zh)
DK (1) DK0894009T3 (zh)
ES (1) ES2246505T3 (zh)
FI (1) FI981954A (zh)
HK (1) HK1018203A1 (zh)
HU (1) HU227978B1 (zh)
IL (4) IL126099A (zh)
NO (1) NO984163L (zh)
NZ (1) NZ331736A (zh)
PL (1) PL188888B1 (zh)
TW (1) TW448045B (zh)
WO (1) WO1997033619A1 (zh)
ZA (1) ZA971820B (zh)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
CA2278937A1 (en) * 1996-12-11 1998-06-18 Pharmacyclics, Inc. Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
CZ295734B6 (cs) * 1997-02-11 2005-10-12 Qlt Inc. Léčivo pro omezení nebo prevenci účinků zánětů v tkáni
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6534040B2 (en) 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7078014B2 (en) * 1999-12-23 2006-07-18 Health Research, Inc. Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7097826B2 (en) 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
WO2001051087A2 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
ATE552855T1 (de) 2000-02-10 2012-04-15 Massachusetts Eye & Ear Infirm Kombinationen und zubereitung zur anwendung in pdt zur behandlung von augenleiden mit unerwünschter choriodaler neovascularisation
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
WO2001074389A2 (en) * 2000-03-24 2001-10-11 Novartis Ag Improved treatment of neovascularization
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
DE60225783T2 (de) * 2001-02-06 2009-04-09 Qlt Inc., Vancouver Photodynamische therapie mit verminderter bestrahlungsstärke
US8106038B2 (en) 2001-02-15 2012-01-31 Qlt Inc. Method for reducing or preventing PDT related inflammation
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6599891B2 (en) * 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
WO2003039404A2 (en) * 2001-11-09 2003-05-15 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
WO2003061696A2 (en) * 2002-01-23 2003-07-31 Light Sciences Corporation Systems and methods for photodynamic therapy
BR0308675A (pt) * 2002-03-20 2005-02-15 Novadaq Technologies Inc Método e aparelho para visualizar o fluxo de fluido através de vasos, memória que pode ser lida por computador, produto de programa de computador e método para o tratamento de uma lesão de um animal
US7381404B2 (en) * 2002-07-02 2008-06-03 The Regents Of The University Of California Treatment for dry macular degeneration
CA2499469C (en) * 2002-07-17 2013-06-04 Novadaq Technologies Inc. Combined photocoagulation and photodynamic therapy
CA2500877A1 (en) * 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
US20060258629A1 (en) * 2002-10-18 2006-11-16 Freeman William R Photodynamic therapy for ocular neovascularization
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
ATE442861T1 (de) * 2003-03-07 2009-10-15 Univ Texas Gegen antikörper gerichtete photodynamische therapie
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
JP4855937B2 (ja) * 2003-05-14 2012-01-18 ソシエテ デ コマーシャリセーション デス プロデューツ デ ラ リーサーシェ アプリケ エスオーシーピーアールエー−サイエンセス サンテ エ ヒューマネス エス．イー．シー． 医療における光線力学適用のための両親媒性トリスルホン化ポルフィラジン
CN100534428C (zh) * 2003-08-25 2009-09-02 上海复旦张江生物医药股份有限公司 血卟啉单甲醚在治疗眼科疾病中的应用
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
WO2005066348A2 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
EP1755584A4 (en) * 2004-05-07 2007-10-31 Univ California TREATMENT OF MYOPIA
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
US20070213693A1 (en) * 2004-08-27 2007-09-13 Ellex Medical Pty Ltd Selective ophthalmic laser treatment
TW200610555A (en) * 2004-09-24 2006-04-01 Light Sciences Corp Extended treatment of tumors through vessel occlusion with light activated drugs
CN103301094A (zh) * 2004-11-17 2013-09-18 乔安妮·麦克劳林 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法
JP2008524224A (ja) * 2004-12-15 2008-07-10 ライト サイエンシズ オンコロジー、インコーポレイテッド 閉塞作用を強化した光線力学的療法
US7803375B2 (en) * 2005-02-23 2010-09-28 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20070122344A1 (en) 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
WO2007119108A2 (en) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
WO2007097839A2 (en) * 2006-02-16 2007-08-30 Massachusetts Eye And Ear Infirmary Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
JP2009526834A (ja) * 2006-02-17 2009-07-23 ジョアン マクローリン， タンパク質凝集の疾患の治療のための組成物および方法
BRPI0708725A2 (pt) * 2006-03-09 2011-06-07 Waratah Pharmaceuticals Inc formulação de poliálcool de ciclohexano para o tratamento de doenças de agregação de proteìna
CA2652449A1 (en) * 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators
US20080161744A1 (en) 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
EP2083777A4 (en) 2006-10-25 2011-01-05 Ellex R & D Pty Ltd RETINAL REGENERATION
JP2010510254A (ja) * 2006-11-24 2010-04-02 ワラタ ファーマシューティカルズ， インコーポレイテッド アルツハイマー病および関連の神経変性疾患のための併用処置
WO2008103299A2 (en) * 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
WO2008124931A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
CA2683548A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
US20100331267A1 (en) * 2007-04-12 2010-12-30 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
EP2148667B1 (en) * 2007-04-12 2013-05-22 Waratah Pharmaceuticals, Inc. Use of cyclohexanehexol derivatives in the treatment of ocular diseases
AU2008255642B2 (en) * 2007-05-30 2013-03-07 Alpharet Pty Ltd Retinal rejuvenation laser
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
WO2009126894A2 (en) * 2008-04-11 2009-10-15 Massachusetts Eye And Ear Infirmary Methods and compositions for the diagnosis and treatment of angiogenic disorders
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
ES2671710T3 (es) 2008-05-02 2018-06-08 Novadaq Technologies ULC Métodos para la producción y uso de eritrocitos cargados con sustancias para la observación y el tratamiento de la hemodinámica microvascular
US20100093648A1 (en) * 2008-10-09 2010-04-15 Antonio Cruz Treatment of macular degeneration-related disorders
KR101018785B1 (ko) * 2008-11-28 2011-03-03 삼성전기주식회사 전자기 밴드갭 구조물 및 회로 기판
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US20140004510A1 (en) 2010-09-24 2014-01-02 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
JP6215203B2 (ja) * 2011-08-23 2017-10-18 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ． Ｌｔｄ 眼疾患および障害の治療用の（バクテリオ）クロロフィル光増感剤
US9211214B2 (en) 2012-03-21 2015-12-15 Valeant Pharmaceuticals International, Inc Photodynamic therapy laser
EP2863801B8 (en) 2012-06-21 2024-06-12 Stryker Corporation Quantification and analysis of angiography and perfusion
US9962251B2 (en) 2013-10-17 2018-05-08 Boston Scientific Scimed, Inc. Devices and methods for delivering implants
KR102068776B1 (ko) 2014-09-29 2020-01-21 노바다크 테크놀러지즈 유엘씨 자가형광이 존재하는 생물학적 물질에서 타겟 형광체의 이미징
US10631746B2 (en) 2014-10-09 2020-04-28 Novadaq Technologies ULC Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
JP7079937B2 (ja) 2016-05-26 2022-06-03 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 肺血管疾患を治療するための組成物および方法
EP4242743A3 (en) 2017-02-10 2023-10-18 Stryker European Operations Limited Open-field handheld fluorescence imaging systems and methods
KR20190056758A (ko) 2017-11-17 2019-05-27 주식회사 지뉴브 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179120A (en) 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
US5776966A (en) 1992-05-27 1998-07-07 University Of British Columbia Selective cell inactivation in blood
CA2185644C (en) * 1994-03-14 2011-04-12 Joan W. Miller Use of green porphyrins in ocular diagnosis and therapy
JP2961074B2 (ja) * 1995-09-06 1999-10-12 明治製菓株式会社 光化学療法用の新生血管閉塞剤

Also Published As

Publication number Publication date
CN1213314A (zh) 1999-04-07
HUP9902012A3 (en) 2000-04-28
US20030149012A1 (en) 2003-08-07
TW448045B (en) 2001-08-01
US5756541A (en) 1998-05-26
US6548542B1 (en) 2003-04-15
ZA971820B (en) 1997-10-10
CA2248087C (en) 2007-10-16
KR100433507B1 (ko) 2004-12-23
CZ278998A3 (cs) 1999-05-12
HUP9902012A2 (hu) 1999-12-28
CA2248087A1 (en) 1997-09-18
IL220143A0 (en) 2012-07-31
JP2006273853A (ja) 2006-10-12
FI981954A (fi) 1998-11-10
IL126099A (en) 2012-08-30
AR004422A1 (es) 1998-12-16
AU705100B2 (en) 1999-05-13
IL126099A0 (en) 1999-05-09
FI981954A0 (fi) 1998-09-11
DK0894009T3 (da) 2005-10-31
WO1997033619A1 (en) 1997-09-18
US5910510A (en) 1999-06-08
NZ331736A (en) 2000-06-23
EP0894009B1 (en) 2005-08-10
JP2000506173A (ja) 2000-05-23
HK1018203A1 (en) 1999-12-17
IL220210A0 (en) 2012-07-31
CN1104908C (zh) 2003-04-09
US20120310144A1 (en) 2012-12-06
DE69733943D1 (de) 2005-09-15
DE69733943T2 (de) 2006-06-01
PL328796A1 (en) 1999-02-15
AU1762697A (en) 1997-10-01
ATE301473T1 (de) 2005-08-15
KR19990087682A (ko) 1999-12-27
ES2246505T3 (es) 2006-02-16
NO984163D0 (no) 1998-09-10
US8239978B2 (en) 2012-08-14
PL188888B1 (pl) 2005-05-31
CZ299301B6 (cs) 2008-06-11
IL187758A0 (en) 2008-03-20
EP0894009A1 (en) 1999-02-03
US20080058403A1 (en) 2008-03-06
HU227978B1 (en) 2012-07-30
AR042931A2 (es) 2005-07-06

Similar Documents

Publication Publication Date Title
NO984163L (no) Forbedret syn ved fotodynamisk terapi av °yet
NO991381D0 (no) Kombinasjonsterapi for behandling av psykoser
PL344977A1 (en) Therapeutic uses of quinoline derivatives
GB2331813B (en) Combination of optical elements
HUP0003911A3 (en) Treatment of neoplasms with viruses
PL331562A1 (en) Derivatives of tetraquinoline as antagonists of eaa
ID18679A (id) Penggunaan terapi lanjutan
EP0959879A4 (en) PHOTODYNAMIC THERAPY FOR THE TREATMENT OF ARTHROSIS
PT1021444E (pt) Derivados 3-carboxamida de 5h-pirrolo¬2,1-c|¬1,4|-benzodiazepinas
ZA9711168B (en) New therapeutic application of pyrrole derivatives.
NO973680D0 (no) Fremgangsmåte for fremstilling av ikke-vandige dispersjoner og deres anvendelse
NO996545L (no) Behandling av aluminiumslagg
AU2606099A (en) Method of epilation by transcutaneous laser light
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
DE19581497T1 (de) Neue Derivate des Tetramethylcyclopropans
IL126972A0 (en) Stimulation of host defense mechanisms against viral challenges
AU7985698A (en) Methods for treatment of ocular neovascularization
NO980316D0 (no) Fremgangsmåte for fremstilling av polymerisater av N-vinylkarprolaktam
AUPP229598A0 (en) Treatment of sunburn
NO20002011D0 (no) Fremgangsmõte ved behandling av aske
BR9704770A (pt) Derivados de 1-carba-(detia)-cefalosporina
AU2002325406A1 (en) Treatment of Neoplasms with Viruses
ZA989465B (en) Therapeutic uses of quinoline derivatives.
GB9727461D0 (en) Authentication of optical discs
AU2912199A (en) Treatment of sunburn

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application